NetScientific (GB:NSCI) has released an update.
NetScientific reports that its portfolio company, PDS Biotechnology, has presented promising results from the Phase 2 VERSATILE-002 clinical trial of Versamune® HPV in combination with KEYTRUDA® for treating HPV16-positive head and neck cancer. The trial showed a Median Overall Survival of 30 months, an Objective Response Rate of 36%, and a Disease Control Rate of 77%, with plans to start a Phase 3 trial this year. These results suggest potential improvements over existing treatments, indicating a significant advancement in immunotherapy for head and neck cancer.
For further insights into GB:NSCI stock, check out TipRanks’ Stock Analysis page.
